For instance, tyrosine kinase inhibitors (TKIs) are used to treat leukemia with a BCR-ABL fusion gene, and abnormally spliced mRNA precursors after BCR-ABL transcription are often found that lack the target domain of TKIs and allow tumor cells to escape killing by drugs (17, 18). This evidence concerns the gene BCR and neoplasm.